Georgios Kokolakis

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

Journal: Dermatology and therapy

Published: January 30, 2026

Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies.

Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies.

Journal: Dermatology and therapy

Published: January 27, 2026

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 14, 2025

Determinants of Satisfaction with Medical Care for Hidradenitis Suppurativa: Results from a Multicentre Survey in Germany.

Determinants of Satisfaction with Medical Care for Hidradenitis Suppurativa: Results from a Multicentre Survey in Germany.

Journal: Dermatology and therapy

Published: August 25, 2025

Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa.

Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 24, 2025

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.

Journal: Journal of the American Academy of Dermatology

Published: August 20, 2025

Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial.

Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial.

Journal: Journal of the American Academy of Dermatology

Published: July 11, 2025

Bimekizumab in plaque type psoriasis: Meta-analyses of observational effectiveness studies.

Bimekizumab in plaque type psoriasis: Meta-analyses of observational effectiveness studies.

Journal: Journal of the American Academy of Dermatology

Published: July 07, 2025

Patient involvement in treatment decisions is associated with increased therapy satisfaction in Hidradenitis suppurativa.

Patient involvement in treatment decisions is associated with increased therapy satisfaction in Hidradenitis suppurativa.

Journal: Frontiers in medicine

Published: May 10, 2025

Impact of adalimumab treatment on impairment of non-professional activities in psoriasis patients.

Impact of adalimumab treatment on impairment of non-professional activities in psoriasis patients.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: April 03, 2025

Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.

Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.

Journal: Dermatology and therapy

Published: January 27, 2025

Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Journal: Dermatology and therapy

Published: January 17, 2025

Showing 1-12 of 67

Last Updated: 09/26/2026